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to determine what tasks were conducted by pharmacy staff and
how much time was spent in the preparation of the top ﬁfteen
chemotherapeutic drugs and regimens used across the four sites.
Pharmacy staff was observed as to the time spent in each task
relative to the total time in an average shift to determine the pro-
portion of total work hours dedicated to the preparation of the
selected chemotherapy drugs. RESULTS: The total average ﬁxed
costs for the preparation of chemotherapy doses across all sites
was $36.03 (range $32.08 for Virginia and $67.19 for Utah).
Data from the four centers was projected to the 3,990,495
million estimated chemotherapy infusions administered to a
national Medicare population in 2003 resulting in a total annual
cost to Medicare for chemotherapy preparation of
$143,777,535. Pharmacists were observed to spend the major-
ity of their day (90% or higher) on tasks directly related to the
preparation of these agents. CONCLUSIONS: Preparation costs
for chemotherapy are signiﬁcant and need to be considered in
determining reimbursement rates for administration.
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OBJECTIVES: To estimate the per-patient cost of hospital care
associated with the treatment of breast cancer recurrence in the
UK. METHODS: Patient-level resource utilisation data for 571
node-positive early breast cancer patients treated at the Western
general Hospital, Edinburgh between 1991 and 2004, of whom
180 experienced disease recurrence, were analysed in order to
provide estimates of the cost of hospital care post-relapse. Unit
costs from national sources were applied to patient-level resource
use data for hospital care collected over a period of ﬁve years
post-relapse. The total cost was estimated by bootstrapping
(1000 simulations; with replacement). RESULTS: Of the 180
patients who experienced a relapse, 145 (81%) died within
follow-up, 143 of these due to breast cancer. The ﬁrst relapse
was distant in 145 patients and locoregional in 35 (25 of which
experienced a subsequent distant disease and 3 experienced
further locoregional recurrence within follow-up). The bootstrap
mean cost post-relapse (and 95% conﬁdence intervals) was
£14,085 (£12,370–£15,877) for patients whose ﬁrst relapse was
distant and £14,575 (£11,411–£17,872) for patients whose ﬁrst
relapse was locoregional. Comparison with previous published
estimates suggests that the cost of chemotherapy treatments has
increased substantially in recent years. CONCLUSIONS: Hos-
pital costs for patients with relapsed breast cancer may be higher
than previously estimated, perhaps due to recent increases in the
costs of chemotherapy agents. Costs for patients whose ﬁrst
relapse is locoregional are similar on average to that for patients
whose ﬁrst relapse is distant, as many have subsequent locore-
gional or distant relapses.
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OBJECTIVES: The aim of this study is to calculate the market
share of drug cost from the total health insurance cost of treat-
ment of breast, cervical and colorectal cancer. DATA AND
METHODS: Data derives from the central, nationwide database
of the Hungarian National Health Insurance Fund Administra-
tion (OEP) covering the year 2001. The cost of treatment
includes the cost of outpatient care, the acute and chronic inpa-
tient care, the (subsidies) of medicines’ prices (reimbursement)
and the expenditure on disability to work. The subsidies of drugs
include the following ATC codes: “L” (Antineoplastic and
immunomodulating agents), “N02” (Analgesics) and “A04”
(Antiemetics and antineuseants). The diseases were identiﬁed
with the following ICD (International Classiﬁcation of diseases):
breast (C50, D05, D24), cervix (C53, D06, D26.0) colorectal
(C18, C19, C20, C21, D01.0, D01.1, D01.2, D01.3, D01.4,
D12). RESULTS: The total health insurance cost of treatment of
breast cancer was around 33.4 million € (8.6 billion Hungarian
forint) in 2001. The total health insurance cost of treatment of
cervical cancer was around €4.1 million (1 billion Hungarian
forint) in 2001. The total health insurance cost of treatment of
colorectal cancer was around €38.871.666 (9.98 billion Hun-
garian forints) in 2001. The drug cost of breast cancer was €9.45
million, cervical cancer €0.62 million and colorectal cancer was
€4.86 million. The market share of drug reimbursement cost
from the total health insurance cost was the following: breast
cancer (28.3%), cervical cancer (15.4%), colorectal cancer
(12.5%). CONCLUSIONS: The health insurance reimbursement
of drugs varies in different types of cancer. The drug costs rep-
resent the highest cost element in breast cancer compared to cer-
vical and colorectal cancer.
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OBJECTIVES: Intravenous (IV) bisphosphonates reduce skeletal
related events (SREs) and alleviate bone pain in patients with
breast cancer and bone metastases (BCBM). However, these
agents differ in terms of efﬁcacy, administration time and costs.
We compared the cost-effectiveness of IV bisphosphonates from
a German inpatient perspective. METHODS: A 7-year literature-
based model was designed to simulate the natural history, costs
and quality-adjusted life expectancy (QALE) of 4 hypothetical
cohorts of BCBM patients receiving no treatment (NT) or
monthly IV ibandronate (IB), pamidronate (PA) or zoledronic
acid (ZA). The model included probabilities of death and disease
progression and the risk of SREs. The risk reduction in SREs
with each bisphosphonate was estimated using the Andersen Gill
hazard ratio v. NT (0.71 for IB, 0.70 for PA, and 0.56 for ZA).
The model included direct medical costs for drugs, IV adminis-
tration and SREs. Survival was adjusted for the time spent with
and without SREs and on and off therapy to capture the bis-
phosphonates’ impact on QALE. All outcomes were discounted
at 5% per annum. RESULTS: The cumulative number of SREs
over the 7-year simulation was lowest for ZA (3.53 per patient),
followed by PA (4.17), IB (4.21) and NT (5.80). Average QALE
was highest with ZA (1.10), followed by PA (1.09), IB (1.09)
and NT (0.92). Total per-patient costs were lowest for ZA
(€15,520), followed by PA (€16,968), NT (€17,317) and IBN
(€17,881). In probabilistic sensitivity analyses, the 95th per-
centile value for the cost per QALY saved was €15,600 (ZA),
€84,000 (IB), and €87,500 (PA). ZA, PA and IB were cost savings
